The impact of sentinel lymph node biopsy on the quality of life in patients with oral cavity squamous cell carcinoma

Seferin, Marco Roberto; Pinto, Fábio Roberto; Leite, Ana Kober Nogueira; Dedivitis, Rogério Aparecido; Kulcsar, Marco Aurélio Vamondes; Cernea, Cláudio Roberto; Matos, Leandro Luongo de

doi:10.1016/j.bjorl.2020.11.015

Cited by 7 publications

(31 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent years have seen a growing body of evidence to indicate that SNLB, with completion neck dissection where necessary, has similar patient survival outcomes as END for the management of the N0 neck in early stage OSCC 8–11,20 . Furthermore, cost and quality of life analyses appear to favour SNLB over END in these patients 12,21,22 . Given these observations, several authorities recommend SLNB as the standard of care in cT1‐2 N0 OSCC, while some professional bodies recommend that all patients with this disease should have access to the procedure 7,13,14,23 .…”

Section: Discussionmentioning

confidence: 99%

“…[8][9][10][11]20 Furthermore, cost and quality of life analyses appear to favour SNLB over END in these patients. 12,21,22 Given these observations, several authorities recommend SLNB as the standard of care in cT1-2 N0 OSCC, while some professional bodies recommend that all patients with this disease should have access to the procedure. 7,13,14,23 However, despite these guidelines, SLNB remains an underused technique for accurate staging and subsequent management in cT1-2 N0 OSCC.…”

Section: Discussionmentioning

confidence: 99%

“…Recent reports indicate similar survival outcomes between SLNB and END, 8–11 while emerging evidence suggests reduced morbidity in the former 10,12 . These findings have led several authorities to recommend SLNB over END in the management of T1‐2 N0 OSCC 7,13,14 .…”

Section: Introductionmentioning

confidence: 97%

“…Recent reports indicate similar survival outcomes between SLNB and END, [8][9][10][11] while emerging evidence suggests reduced morbidity in the former. 10,12 These findings have led several authorities to recommend SLNB over END in the management of T1-2 N0 OSCC. 7,13,14 However, due to logistic challenges such as training of the multidisciplinary team and compliance to stringent regulatory protocols, SLNB is currently only limited to a few centres.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Centralised pathology service for sentinel node biopsy in oral cavity cancer: The Southeast England Consortium experience

Patel

Bowe

Garg

et al. 2022

J Oral Pathology Medicine

View full text Add to dashboard Cite

Background Sentinel lymph node biopsy is an increasingly recognised option for accurate staging and subsequent management of the clinically negative neck in early stage oral cavity squamous cell carcinoma. However, the technique is currently underused due to several logistic constraints including increased burden on pathology services. Here, we describe the feasibility of an outsourced centralised pathology processing and reporting service for sentinel lymph node biopsies in oral cavity squamous cell carcinoma. Patients and methods The Southeast England Consortium comprises four surgical centres utilising a central pathology service. Consecutive cases between January 2016 and February 2020 were retrospectively evaluated for survival outcomes and laboratory turnaround times. Results Twenty‐eight per cent from a cohort of 139 patients had positive sentinel nodes. There was a trend towards greater overall, disease‐free and disease‐specific survival (OS, DFS and DSS, respectively) in sentinel node negative compared to sentinel node positive patients, but these differences were not statistically significant. The sensitivity, negative predictive value and false negative rate were 92.8%, 97.0% and 6.8%, respectively. The mean and mode laboratory TAT were 5 and 4 working days, respectively. Conclusion An outsourced centralised pathology service is a feasible option to widen the availability of sentinel node biopsy in oral cavity squamous cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

mentioning

confidence: 99%

See 2 more Smart Citations

Centralised pathology service for sentinel node biopsy in oral cavity cancer: The Southeast England Consortium experience

Patel

Bowe

Garg

et al. 2022

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…In the last two decades, sentinel lymph node biopsy (SLNB) has been used to guide the treatment of patients with early‐stage oral SCC. SLNB involves a less invasive technique, shorter hospital stay and fewer complications, as well as better functional outcomes 5–7 . SLNB is associated with similar detection rates of occult lymph node metastasis and survival as that of elective neck dissection (END) 8–10 …”

Section: Introductionmentioning

confidence: 99%

Sentinel lymph node biopsy for early squamous cell carcinoma of the lip and oral cavity: Real‐world experience in Brazil

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background This study aimed to evaluate the accuracy and oncological results of sentinel lymph node biopsy in patients with early lip and oral cavity squamous cell carcinoma (SCC) in a real‐world scenario. Methods Retrospective study including seven Brazilian centers. Results Four‐hundred and seven cN0 patients were accrued for 20 years. The rate of occult metastasis was 23.1% and 22 patients (5.4%) had regional failure. We found, for 5 years of follow‐up, 85.3% of regional recurrence‐free survival; 77.1% of disease‐free survival; 73.7% of overall survival; and 86.7% of disease‐specific survival. The rate of false‐negative cases was 5.4%. Conclusion In a real‐world scenario, sentinel lymph node biopsy for patients with SCC of the lip and oral cavity proved feasible in different settings and to be oncologically safe, with similar rates of occult lymph node metastasis and false‐negative cases, when compared to elective neck dissection, and with similar long‐term survival to that reported historically.

show abstract

Role of sentinel lymph node biopsy for oral squamous cell carcinoma: Current evidence and future challenges

et al. 2022

View full text Add to dashboard Cite

Sentinel lymph node biopsy (SLNB) has been used across oncological specialties for prognostication, staging, and identification of occult nodal metastasis. Recent studies demonstrated the potential clinical utility of SLNB in oral cavity squamous cell carcinoma (OCSCC). Elective neck dissection is the current standard of care in early management of OCSCC with depth of invasion greater than 2-4 mm; however, majority of patients ultimately do not have nodal disease on final pathology. SLNB is an alternative procedure widely adopted in early cancer management in many oncological subspecialities. Several considerations such as depth of invasion, nodal mapping, histopathology methods, operator variability, postoperative complications, and advancement in preoperative and intraoperative imaging technology can guide the appropriate application to SLNB in OCSCC. The aim of this review is to discuss the current evidence for SLNB in the treatment of early stage OCSCC, imaging technologies that support SLNB procedures, and studies that are currently underway.

show abstract

The impact of sentinel lymph node biopsy on the quality of life in patients with oral cavity squamous cell carcinoma

Cited by 7 publications

References 29 publications

Centralised pathology service for sentinel node biopsy in oral cavity cancer: The Southeast England Consortium experience

Centralised pathology service for sentinel node biopsy in oral cavity cancer: The Southeast England Consortium experience

Sentinel lymph node biopsy for early squamous cell carcinoma of the lip and oral cavity: Real‐world experience in Brazil

Role of sentinel lymph node biopsy for oral squamous cell carcinoma: Current evidence and future challenges

Contact Info

Product

Resources

About